Day: March 18, 2025

 Kyivstar, Ukraine’s largest digital operator, serves 24 million customers with fixed and mobile communication services. Expected to be the only U.S.-listed pure play Ukrainian investment opportunity. Consumer digital service portfolio includes healthcare platform Helsi with more than 28 million registered patients and streaming platform Kyivstar TV with 2 million monthly active users, while enterprise services include cloud, cybersecurity and AI solutions, and the software development business Kyivstar Tech. Strong growth potential, including expansion into digital services and international partnerships such as Starlink direct-to-cell deployment. Transaction assigns a pro-forma valuation of USD 2.21 billion to Kyivstar at closing.Kyiv, New York, Dubai and Philadelphia, 18 March 2025: VEON Ltd. (Nasdaq: VEON), a global digital...

— Prime Editing has potential to be best-in-class approach for AATD — — Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP — — High levels of editing at the target site in preclinical studies with full restoration of circulating wild-type AAT protein (M-AAT) to normal human range — — Expects to file IND and/or CTA in mid-2026 — CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new...

New registry study to focus on impact of fatigue in people with craniopharyngioma BOSTON, March 18, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma. “We are excited to partner with the Raymond A. Wood Foundation on this survey to learn more about fatigue and its effects related to craniopharyngiomas,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “Learning directly from patients and...

Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported results from recent preclinical studies of BP1001-A that support its potential as a treatment for obesity. In these studies, BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models, which signal increased potential for BP1001-A as a treatment for obesity and related metabolic diseases...

-Accretive transaction valued at approximately U.S. $85 million- -Bitfarms to reinvest capital in U.S. growth opportunities- This news release constitutes a “designated news release” for the purposes of Bitfarms’ second amended and restated prospectus supplement dated December 17, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario, March 18, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a global Bitcoin and vertically integrated data center company, today announced the successful completion of the sale of its 200 MW data center in Yguazu, Paraguay to HIVE Digital Technologies, Ltd. (“HIVE”). Bitfarms CEO Ben Gagnon stated, “We are pleased to have expeditiously completed the sale of our Yguazu site to HIVE, allowing us to streamline our operations and further rebalance our portfolio...

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA) is pleased to announce that it has received approval to list its common shares on the OTC Markets under the ticker symbol OTCQB:MTDTF. The Company expects trading to commence on March 18, 2025. The OTC listing marks a significant milestone for Matador as it executes its strategic plan to enhance liquidity, broaden its shareholder base, and provide U.S. investors with greater accessibility to its stock. The listing aligns with the Company’s commitment to expanding its presence in global capital markets while reinforcing its position within the digital asset and financial technology sectors. As part of this strategic expansion, Matador recognizes the growing interest in publicly traded companies operating within the...

Kering – Statement Number of Shares and voting rights – 14.03.2025  Kering Société anonyme with a share capital of €493,683,112Head office: 40, rue de Sèvres – 75007 PARIS552 075 020 RCS PARIS  March 18, 2025 Monthly statement on the total number of shares and voting rights(articles L.233-8 of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)Date   Total number of shares Total number of voting rightstheoretical 1 exercisable 2March 14, 2025 123,420,778 176,686,709 175,867,6241 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223‑11 of AMF General Regulation). 2 Excluding treasury shares stripped of voting rights.Attachment...

Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the Company along with its partners, have submitted applications for four new federal funding opportunities. The funding, if awarded, would total up to US$117.5 million and support the company’s efforts to advance urgent infectious disease treatments aligned with critical public health priorities. Funding Opportunities By leveraging Appili’s...

Boston, MA., March 18, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is excited to announce it was selected by Massachusetts Department of Transportation (MassDOT) Aeronautics Division for and, successfully completed a demonstration for the simulated delivery of medical supplies for use in support of home-based healthcare. The medical delivery demonstrations took place between August and October 2024 and involved three selected companies, including Draganfly. “This medical delivery demonstration underscores the value of drones for many operational needs,” said Transportation Secretary and CEO Monica Tibbits-Nutt, “Drones already have proven useful with operations, including MBTA track corridor...